Two former Insys Therapeutics salespeople indicted in a kickback scheme pleaded not guilty in Manhattan federal court Wednesday. The two are the latest ex-…

Johnson & Johnson lost its court battle to shield Remicade from encroaching biosimilar competition. A U.S. court struck down J&J's key patent on…

A Pfizer deal is at the center of another round of insider trading charges. This time, the buyout is Pfizer’s 2010 King Pharmaceuticals deal, and it’s a lawyer…

Novartis got another black eye in Asia this week as South Korea indicted a half-dozen executives on drug-rebate charges. But now the company may have a bigger…

Amgen parlayed a discount and some new data into NICE backing for its virus-based melanoma drug Imlygic, putting patients in England in line for the pricey,…

Two years after threatening to sue AbbVie for abandoning its $55 billion Shire buyout, hedge fund Elliott Management finally did.

It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up,…

Merck & Co.’s Keytruda saw its fortunes rise significantly Friday, and not just because its Bristol-Myers Squibb rival failed a key lung cancer study.…